VAXCYTE, INC. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
VAXCYTE, INC. (PCVX) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$712.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-05
- VAXCYTE, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$712.00K.
- VAXCYTE, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$8.42M, a 337.14% decline year-over-year.
- VAXCYTE, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $2.74M.
- VAXCYTE, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-06-30 was -$1.56M.
- VAXCYTE, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $5.46M.
- VAXCYTE, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$4.05M, a 850.37% decline from fiscal 2023.
- VAXCYTE, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $540.00K.
- VAXCYTE, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$120.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$712.00K 10-Q · filed 2026-08-05 | -$9.13M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2026-03-31 | -$8.42M 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $5.46M 10-K · filed 2026-02-24 | |||
| 2025-09-30 | $2.74M 10-Q · filed 2025-11-04 | $1.18M derived: sum of 2 quarters · filed 2026-08-05 | $4.73M derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-06-30 | -$1.56M 10-Q · filed 2026-08-05 | $1.99M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $3.55M 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | -$4.05M 10-K · filed 2026-02-24 | |||
| 2024-09-30 | -$1.68M 10-Q · filed 2025-11-04 | -$2.75M derived: sum of 2 quarters · filed 2025-11-04 | -$40.00K derived: sum of 3 quarters · filed 2025-11-04 | |
| 2024-06-30 | -$1.07M 10-Q · filed 2025-11-04 | $1.64M derived: sum of 2 quarters · filed 2025-11-04 | ||
| 2024-03-31 | $2.71M 10-Q · filed 2025-11-04 | |||
| 2023-12-31 | $540.00K 10-K · filed 2026-02-24 | |||
| 2022-12-31 | -$120.00K 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |